RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 58 filers reported holding RUBIUS THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $44 | -87.7% | 2,042,666 | 0.0% | 0.00% | -85.0% |
Q4 2022 | $357 | -100.0% | 2,042,666 | 0.0% | 0.02% | -47.4% |
Q3 2022 | $886,000 | -71.9% | 2,042,666 | -44.8% | 0.04% | -77.4% |
Q2 2022 | $3,149,000 | -84.6% | 3,701,580 | 0.0% | 0.17% | -80.3% |
Q1 2022 | $20,396,000 | -43.1% | 3,701,580 | 0.0% | 0.85% | -12.1% |
Q4 2021 | $35,831,000 | -51.8% | 3,701,580 | -10.9% | 0.97% | -41.5% |
Q3 2021 | $74,303,000 | -34.3% | 4,155,625 | -10.3% | 1.66% | -27.6% |
Q2 2021 | $113,111,000 | -12.6% | 4,633,791 | -5.1% | 2.30% | +0.4% |
Q1 2021 | $129,420,000 | +351.2% | 4,883,791 | +29.2% | 2.29% | +271.3% |
Q4 2020 | $28,682,000 | +51.5% | 3,778,913 | 0.0% | 0.62% | +33.9% |
Q3 2020 | $18,932,000 | -17.8% | 3,778,913 | -1.9% | 0.46% | -28.7% |
Q2 2020 | $23,037,000 | +33.3% | 3,852,341 | -0.8% | 0.64% | -11.6% |
Q1 2020 | $17,283,000 | -35.8% | 3,883,791 | +37.1% | 0.73% | -29.8% |
Q4 2019 | $26,921,000 | +21.0% | 2,833,791 | 0.0% | 1.04% | +16.6% |
Q3 2019 | $22,246,000 | -50.1% | 2,833,791 | 0.0% | 0.89% | -50.5% |
Q2 2019 | $44,576,000 | -15.3% | 2,833,791 | -2.6% | 1.80% | -16.1% |
Q1 2019 | $52,650,000 | +12.6% | 2,908,791 | 0.0% | 2.15% | +24.1% |
Q4 2018 | $46,773,000 | -33.0% | 2,908,791 | 0.0% | 1.73% | -4.6% |
Q3 2018 | $69,811,000 | – | 2,908,791 | – | 1.82% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |